Leuprolide
FDA approved · RxGnRH receptor agonist
Also known as: Lupron, Eligard, Fensolvi, leuprorelin, Lupron Depot, Camcevi, Vabrinty, Leuprolide Acetate, Leuprorelin, Leuprorelina
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 521 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 2 cited sources. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Leuprolide, also called leuprorelin, is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH). It first stimulates and then, with continued exposure, suppresses the pituitary's release of LH and FSH, which lowers testosterone and estrogen production.
What the evidence shows
Leuprolide is FDA-approved, under brands such as Lupron Depot, Eligard, Camcevi, and Fensolvi, for conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty, with specific indications varying by product. It is supported by a large body of evidence, with about 520 registered human trials reaching Phase 4 and over 2,400 published papers.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis
A Phase Ia Trial Comparing the Pharmacokinetics/Pharmacodynamics, Safety, and Preliminary Efficacy of HHK001 and Enantone in Patients With Endometriosis
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Effects of gonadal steroids in women with a history of postpartum depression.
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Changes in body composition during androgen deprivation therapy for prostate cancer.
Sources
- PubChem compound record (CID 657181)
- FDA drug label on DailyMed
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.